Records type 1 diabetes care across China in patients and young people
Collects information on people with type 1 diabetes, including those diagnosed by age 20.
Plain-language title generated from the registry record
Registry title: China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes
Key facts
- Where
- Changsha, Changzhi, Haikou, Hangzhou, Harbin, Kunming, Lanzhou, Luoyang, Nanjing, Shenzhen, and Ürümqi, ChinaSee the 11 sites
Where in China
- The Second Xiangya Hospital, Central South UniversityChangsha, ChinaTaking people
- Heji Hospital Affiliated to Changzhi Medical CollegeChangzhi, ChinaTaking people
- Hainan General HospitalHaikou, ChinaTaking people
- Zhejiang Provincial People's HospitalHangzhou, ChinaTaking people
- The First Affiliated Hospital of Harbin Medical UniversityHarbin, ChinaTaking people
- The First People's Hospital of YunnanKunming, ChinaTaking people
- Gansu Provincial People's HospitalLanzhou, ChinaTaking people
- The First Affiliated Hospital of Henan University of Science and TechnologyLuoyang, ChinaTaking people
- The First Affiliated Hospital of Nanjing Medical UniversityNanjing, ChinaNot yet recruiting
- Shenzhen Second People's HospitalShenzhen, ChinaTaking people
- The First Affiliated Hospital of Xinjiang Medical UniversityÜrümqi, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Second Xiangya Hospital of Central South University
- Trial code
- NCT05498974
- Record updated
- 28 April 2026
- Original description
The aim of the China Diabetes Type 1 Study (CD1S) is to conduct a nationwide type 1 diabetes (T1D) registry study in patients with T1D and in pediatric adolescent patients with diabetes who had an age of onset <= 20 years.Read full original descriptionShow less
China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes
The aim of the China Diabetes Type 1 Study (CD1S) is to conduct a nationwide type 1 diabetes (T1D) registry study in patients with T1D and in pediatric adolescent patients with diabetes who had an age of onset <= 20 years.
CD1S compromises a retrospective study enrolling inpatients hospitalized from Jan 1st, 2016 to Dec 31, 2021, and a prospective study beginning from the year 2022.
Inclusion: 1. Patients with type 1 diabetes mellitus of any duration; meeting criteria (1) or any of (2) or any of (3); Clinical diagnosis of type 1 diabetes by a specialist; Age at onset < 15 years; no overweight or obesity at onset; previous diabetic ketoacidosis; highest random C-peptide < 200 pmol/L; Initiation and continuation of insulin therapy (except pancreatic or islet transplantation) after diagnosis; positive islet autoantibodies Or 2. Children and adolescents with diabetes mellitus at age of onset <= 20 years, regardless of type and duration of disease.
Exclusion: For enrolment of patients with T1D, exclusion was made if any of the following criteria were met (not applicable to those with onset under 20 years of age); No insulin dependence for at least 6 months after diagnosis of diabetes mellitus; No DKA for 1 month off insulin for those with a history of diabetes > 1 year. ③ C-peptide > 800 pmol/L at any time point.